Swiss National Bank trimmed its position in shares of Mylan NV (NASDAQ:MYL) by 2.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,678,342 shares of the company’s stock after selling 42,400 shares during the quarter. Swiss National Bank owned approximately 0.33% of Mylan worth $31,956,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in MYL. State of New Jersey Common Pension Fund D boosted its stake in shares of Mylan by 194.0% during the first quarter. State of New Jersey Common Pension Fund D now owns 1,700,000 shares of the company’s stock valued at $48,178,000 after purchasing an additional 1,121,745 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Mylan by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock worth $215,460,000 after acquiring an additional 1,026,731 shares during the period. Ion Asset Management Ltd. lifted its stake in shares of Mylan by 67.6% in the second quarter. Ion Asset Management Ltd. now owns 2,247,231 shares of the company’s stock worth $42,787,000 after acquiring an additional 906,555 shares during the period. FIL Ltd lifted its stake in shares of Mylan by 14.1% in the first quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock worth $183,327,000 after acquiring an additional 799,051 shares during the period. Finally, Sector Gamma AS acquired a new position in shares of Mylan in the first quarter worth approximately $22,408,000. 83.27% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on the company. Evercore ISI reaffirmed a “buy” rating on shares of Mylan in a research note on Friday, August 9th. Zacks Investment Research raised Mylan from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 30th. TheStreet lowered Mylan from a “c-” rating to a “d+” rating in a research note on Friday, August 2nd. Credit Suisse Group reaffirmed a “buy” rating and issued a $34.50 price objective on shares of Mylan in a research note on Wednesday, July 31st. Finally, Raymond James set a $31.00 price objective on Mylan and gave the stock a “buy” rating in a research note on Wednesday, May 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Mylan presently has an average rating of “Buy” and a consensus target price of $30.43.
Shares of MYL stock opened at $19.02 on Thursday. The company has a market cap of $9.90 billion, a P/E ratio of 4.15, a PEG ratio of 0.91 and a beta of 1.77. The stock has a 50 day simple moving average of $19.07 and a two-hundred day simple moving average of $23.36. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.37. Mylan NV has a fifty-two week low of $16.63 and a fifty-two week high of $39.59.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.08. The business had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.07 earnings per share. On average, research analysts predict that Mylan NV will post 4.3 earnings per share for the current year.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.